JPS5995220A - 免疫療法剤 - Google Patents
免疫療法剤Info
- Publication number
- JPS5995220A JPS5995220A JP57205219A JP20521982A JPS5995220A JP S5995220 A JPS5995220 A JP S5995220A JP 57205219 A JP57205219 A JP 57205219A JP 20521982 A JP20521982 A JP 20521982A JP S5995220 A JPS5995220 A JP S5995220A
- Authority
- JP
- Japan
- Prior art keywords
- human
- cell
- cells
- lymphokine
- effect
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002955 immunomodulating agent Substances 0.000 title description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 38
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 16
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 12
- 208000026278 immune system disease Diseases 0.000 claims abstract description 10
- 230000003449 preventive effect Effects 0.000 claims abstract description 6
- 210000005260 human cell Anatomy 0.000 claims abstract description 4
- 102000014150 Interferons Human genes 0.000 claims abstract description 3
- 108010050904 Interferons Proteins 0.000 claims abstract description 3
- 150000004676 glycans Chemical class 0.000 claims abstract description 3
- 229940079322 interferon Drugs 0.000 claims abstract description 3
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 3
- 239000005017 polysaccharide Substances 0.000 claims abstract description 3
- 230000018276 interleukin-1 production Effects 0.000 claims abstract 7
- 230000001580 bacterial effect Effects 0.000 claims abstract 4
- 239000004480 active ingredient Substances 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 210000000822 natural killer cell Anatomy 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 7
- 239000003623 enhancer Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 230000003213 activating effect Effects 0.000 claims description 3
- 210000003850 cellular structure Anatomy 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 43
- 230000000694 effects Effects 0.000 abstract description 38
- 201000011510 cancer Diseases 0.000 abstract description 23
- 239000000126 substance Substances 0.000 abstract description 11
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 230000004913 activation Effects 0.000 abstract description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 abstract description 3
- 102000055277 human IL2 Human genes 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract 3
- 230000006051 NK cell activation Effects 0.000 abstract 1
- 229930182478 glucoside Natural products 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 229920001491 Lentinan Polymers 0.000 description 27
- 229940115286 lentinan Drugs 0.000 description 27
- 230000003308 immunostimulating effect Effects 0.000 description 21
- 229960001438 immunostimulant agent Drugs 0.000 description 18
- 102000008072 Lymphokines Human genes 0.000 description 17
- 108010074338 Lymphokines Proteins 0.000 description 17
- 239000003022 immunostimulating agent Substances 0.000 description 17
- 102000000588 Interleukin-2 Human genes 0.000 description 16
- 108010002350 Interleukin-2 Proteins 0.000 description 16
- 230000004083 survival effect Effects 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 10
- 230000006698 induction Effects 0.000 description 10
- 206010061289 metastatic neoplasm Diseases 0.000 description 9
- 108010073243 Nocardia cell wall skeleton Proteins 0.000 description 8
- 239000012642 immune effector Substances 0.000 description 8
- 230000016784 immunoglobulin production Effects 0.000 description 8
- 229940121354 immunomodulator Drugs 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 241001494479 Pecora Species 0.000 description 7
- 239000012228 culture supernatant Substances 0.000 description 7
- 230000002708 enhancing effect Effects 0.000 description 7
- 210000003743 erythrocyte Anatomy 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 230000001472 cytotoxic effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 238000002054 transplantation Methods 0.000 description 6
- 238000002513 implantation Methods 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000009385 viral infection Effects 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 4
- 230000000254 damaging effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000002980 postoperative effect Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 3
- 208000036142 Viral infection Diseases 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 229940127089 cytotoxic agent Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000005265 lung cell Anatomy 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000000628 antibody-producing cell Anatomy 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 230000001698 pyrogenic effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 108010039939 Cell Wall Skeleton Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011765 DBA/2 mouse Methods 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 244000290333 Vanilla fragrans Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000004520 cell wall skeleton Anatomy 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000816 effect on animals Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000009215 host defense mechanism Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000001031 immunopharmacological effect Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000012053 oil suspension Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57205219A JPS5995220A (ja) | 1982-11-22 | 1982-11-22 | 免疫療法剤 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP57205219A JPS5995220A (ja) | 1982-11-22 | 1982-11-22 | 免疫療法剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5995220A true JPS5995220A (ja) | 1984-06-01 |
| JPH045005B2 JPH045005B2 (enExample) | 1992-01-30 |
Family
ID=16503376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP57205219A Granted JPS5995220A (ja) | 1982-11-22 | 1982-11-22 | 免疫療法剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5995220A (enExample) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02256620A (ja) * | 1989-02-20 | 1990-10-17 | Taito Kk | 魚ワクチンの効力を増強する組成物および方法 |
| WO1991016916A1 (fr) * | 1990-05-09 | 1991-11-14 | Otsuka Pharmaceutical Co., Ltd. | Agent antineoplastie |
| EP0609701A1 (en) * | 1993-01-27 | 1994-08-10 | Ajinomoto Co., Inc. | L-cystein, L-cystine or L-glutamine as a supplementary therapeutic agent for the treatment of immunodeficiency syndrome |
| WO1994020105A1 (en) * | 1993-03-10 | 1994-09-15 | Otsuka Pharmaceutical Company, Limited | Interleukin-1 inhibitor |
| US5849282A (en) * | 1990-05-09 | 1998-12-15 | Otsuka Pharmaceutical Co., Ltd. | Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β |
| EP1415655A4 (en) * | 2001-07-19 | 2005-12-21 | Akira Hayashi | IMMUNOTHERAPY FOR PEOPLE |
-
1982
- 1982-11-22 JP JP57205219A patent/JPS5995220A/ja active Granted
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02256620A (ja) * | 1989-02-20 | 1990-10-17 | Taito Kk | 魚ワクチンの効力を増強する組成物および方法 |
| WO1991016916A1 (fr) * | 1990-05-09 | 1991-11-14 | Otsuka Pharmaceutical Co., Ltd. | Agent antineoplastie |
| JPH0418033A (ja) * | 1990-05-09 | 1992-01-22 | Otsuka Pharmaceut Co Ltd | 抗腫瘍剤 |
| US5849282A (en) * | 1990-05-09 | 1998-12-15 | Otsuka Pharmaceutical Co., Ltd. | Method of treating colon, renal, and lung carcinomas with γ-interferon and Ser71 !-interleukin-1β |
| EP0609701A1 (en) * | 1993-01-27 | 1994-08-10 | Ajinomoto Co., Inc. | L-cystein, L-cystine or L-glutamine as a supplementary therapeutic agent for the treatment of immunodeficiency syndrome |
| US5491150A (en) * | 1993-01-27 | 1996-02-13 | Ajinomoto Co., Inc. | Supplementary therpeutic agents for the treatment of immunodeficiency syndrome |
| WO1994020105A1 (en) * | 1993-03-10 | 1994-09-15 | Otsuka Pharmaceutical Company, Limited | Interleukin-1 inhibitor |
| EP1415655A4 (en) * | 2001-07-19 | 2005-12-21 | Akira Hayashi | IMMUNOTHERAPY FOR PEOPLE |
| US7273602B2 (en) | 2001-07-19 | 2007-09-25 | Akira Hayashi | Immunotherapy for humans |
| US7521040B2 (en) | 2001-07-19 | 2009-04-21 | Akira Hayashi | Immunotherapy for humans |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH045005B2 (enExample) | 1992-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mu et al. | Administration of recombinant interleukin 12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes | |
| Donohue et al. | The systemic administration of purified interleukin 2 enhances the ability of sensitized murine lymphocytes to cure a disseminated syngeneic lymphoma. | |
| EP0726772B1 (en) | A method for sensitization of cancer cells for killer cell mediated lysis | |
| JPH09510456A (ja) | 同種リンパ球による癌の免疫療法 | |
| JPH09508390A (ja) | 免疫刺激性モノクローナル抗体 | |
| Reisser et al. | Mechanisms of the antitumoral effect of lipid A | |
| JPH10510147A (ja) | 二次性免疫不全症の治療用薬剤の製造方法 | |
| EP0131789A2 (en) | Composition comprising purified human tumour necrosis factor in conjunction with human interferon and its use | |
| JP2002510639A (ja) | 新生物疾患又は感染性疾患の処置のための新規の配合製剤 | |
| JP3507489B2 (ja) | リンパ球のｉｎ ｖｉｖｏ活性を増大するためのリンパ球の短期抗ＣＤ３刺激 | |
| Nishimura et al. | Combination tumor‐immunotherapy with recombinant tumor necrosis factor and recombinant interleukin 2 in mice | |
| Okamoto et al. | Local injection of OK432 can augment the TH1‐type T‐cell response in tumor‐draining lymph node cells and increase their immunotherapeutical potential | |
| Apte et al. | Opposing Effects of IL-1α and IL-1β on Malignancy Patterns: Tumor cell-associated IL-Iα potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness | |
| JPS5995220A (ja) | 免疫療法剤 | |
| Wang et al. | Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model | |
| JP2002512618A (ja) | 悪性腫瘍の治療方法 | |
| EA015510B1 (ru) | Способ увеличения количества мононуклеарных клеток у субъекта, страдающего раком, и используемая для этого фармацевтическая комбинация | |
| US7589062B2 (en) | Two synthetic peptides for treatment and prevention of cancers | |
| Scheringa et al. | TNF: A brief review with emphasis on its antitumor activity | |
| Abe et al. | Early-appearing tumor-infiltrating natural killer cells play an important role in the nitric oxide production of tumor-associated macrophages through their interferon production | |
| Dinney et al. | Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or γ-interferon | |
| Williams et al. | GM-CSF and stimulation of monocyte/macrophage function in vivo relevance and in vitro observations | |
| Kumagai et al. | Interleukin-12 as an inducer of cytotoxic effectors in anti-tumor immunity | |
| Gottlieb | Cytokine manipulation of the immune response in the treatment of human acute leukaemia | |
| Gazit et al. | Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines |